NCT02655471 is a EARLY_PHASE1 clinical trial of "Raltegravir" and "Zidovudine" in HTLV-I Infections, sponsored by Universidad Peruana Cayetano Heredia.

Who is sponsoring NCT02655471?

NCT02655471 is sponsored by Universidad Peruana Cayetano Heredia.

What drugs are being tested in NCT02655471?

Interventions in NCT02655471: "Raltegravir" and "Zidovudine".

What condition does NCT02655471 study?

NCT02655471 studies HTLV-I Infections, Tropical Spastic Paraparesis.

Is NCT02655471 still recruiting?

NCT02655471 is currently completed. Last updated 22 May 2019.

Last reviewed 2019-05-22 · How we verify

NCT02655471

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection

Completed EARLY_PHASE1 Last updated 22 May 2019

What this trial tests

EARLY_PHASE1 trial testing "Raltegravir" and "Zidovudine" in HTLV-I Infections in 10 participants. Completed in 15 March 2019.

Timeline

1 July 2017

Primary endpoint
15 March 2019

15 March 2019

Quick facts

Lead sponsor	Universidad Peruana Cayetano Heredia
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 July 2017
Primary completion	15 March 2019
Estimated completion	15 March 2019
Sites	1 location across Peru

Drugs / interventions tested

"Raltegravir" and "Zidovudine" — full drug profile →

Conditions studied

HTLV-I Infections — all drugs for HTLV-I Infections →
Tropical Spastic Paraparesis — all drugs for Tropical Spastic Paraparesis →

Sponsor

Universidad Peruana Cayetano Heredia — full company profile →

Who can join

18 and older, any sex, with HTLV-I Infections or Tropical Spastic Paraparesis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot study of intervention in a group of patients with tropical spastic paraparesis/ myelopathy to evaluate virologic and clinical response of raltegravir plus zidovudine in this group of patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Universidad Peruana Cayetano Heredia trials

Trials by the same sponsor.

NCT06367361 — One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis · Phase 2 · not yet recruiting
NCT06989502 — Implementation of the COmmunity HEalth System InnovatiON Project in Low- and Middle- Income Countries · NA · not yet recruiting
NCT06565507 — Oxfendazole in Mild Parenchymal Brain Cysticercosis · Phase 2, PHASE3 · not yet recruiting
NCT05981378 — Genomic Approaches to Dissect Human Host-pathogen Interactions in the Amazonian Rainforest · not yet recruiting
NCT06500013 — WhatsApp Intervention to Assess the Effect of Messages in Adherence to Antiretrovirals in Young People With HIV in Peru · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02655471 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universidad Peruana Cayetano Heredia
Last refreshed: 22 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02655471.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing